Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats

Carol R. Reinero, Lisa Brownlee, Kendra C. Decile, Bernard Seguin, Roy D. Berghaus, Richard W Nelson, Laurel J Gershwin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases. Inhalant GC (IGC) maximize local efficacy and minimize systemic bioavailability. We evaluated systemic endocrine and immune effects of IGC (flunisolide, 250 μg/puff q12h) versus OGC (prednisone, 10 mg/d PO) and placebo. Six healthy cats received each drug for 2 weeks followed by a 1-month washout. Testing included determination of single early morning cortisol concentration, results of ACTH stimulation, the urine cortisol-to-creatinine ratio (UC : Cr), lymphocyte phenotype, lymphocyte blastogenesis, serum total IgA and IgM concentrations, and cytokine profiles. Significant differences between treatments were not apparent for serum immunoglobulin concentrations, or expression (mRNA) for the cytokines, interleukin (IL-) 2, IL-4, and IL-10, or gamma interferon. Single early morning cortisol concentration was lower for IGC (0.68 ± 0.74 μg/dL), compared with that associated with placebo (2.82 ± 1.94 μg/dL; P = .033). The ACTH-stimulated peak cortisol concentrations were lower after treatment in cats receiving IGC (before, 8.5 ± 50.2 μg/dL; after, 2.9 ± 3.3 μg/dL, P = .0004), but not OGC (before, 8.0 ± 6.1 μg/dL; after, 6.0 ± 4.5 μg/dL, P = .07). Similarly, UC:Cr (0.8 ± 0.8) before IGC was lower than the value (5.02 ± 3.62; P = .019) after IGC. Compared with placebo, cats given OGC, but not IGC, had significantly lower total percentages of T and B cells. Lymphocyte proliferation was decreased in cats receiving OGC, but not IGC, in comparison with placebo (6.9 ± 3.3; 24.0 ± 6.5; 18.8 ± 14.0, respectively). Significantly more IL-10 mRNA transcription was detected in cats administered OGC or IGC, compared with placebo. Although IGC suppress the hypothalamic-pituitary-adrenocortical axis, IGC had minimal effects on the systemic adaptive immune system.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalJournal of Veterinary Internal Medicine
Volume20
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

flunisolide
Glucocorticoids
glucocorticoids
Cats
mouth
cats
placebos
Placebos
Hydrocortisone
cortisol
Lymphocytes
Interleukin-10
Adrenocorticotropic Hormone
corticotropin
lymphocyte proliferation
interleukin-10
Bronchial Diseases
Cat Diseases
Cytokines
cytokines

Keywords

  • Adaptive immunity
  • Flunisolide
  • Glucocorticoid
  • Hypothalamic-pituitary- adrenal-axis

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. / Reinero, Carol R.; Brownlee, Lisa; Decile, Kendra C.; Seguin, Bernard; Berghaus, Roy D.; Nelson, Richard W; Gershwin, Laurel J.

In: Journal of Veterinary Internal Medicine, Vol. 20, No. 1, 01.2006, p. 57-64.

Research output: Contribution to journalArticle

@article{00ae164912de47b9b43767478fcde12e,
title = "Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats",
abstract = "Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases. Inhalant GC (IGC) maximize local efficacy and minimize systemic bioavailability. We evaluated systemic endocrine and immune effects of IGC (flunisolide, 250 μg/puff q12h) versus OGC (prednisone, 10 mg/d PO) and placebo. Six healthy cats received each drug for 2 weeks followed by a 1-month washout. Testing included determination of single early morning cortisol concentration, results of ACTH stimulation, the urine cortisol-to-creatinine ratio (UC : Cr), lymphocyte phenotype, lymphocyte blastogenesis, serum total IgA and IgM concentrations, and cytokine profiles. Significant differences between treatments were not apparent for serum immunoglobulin concentrations, or expression (mRNA) for the cytokines, interleukin (IL-) 2, IL-4, and IL-10, or gamma interferon. Single early morning cortisol concentration was lower for IGC (0.68 ± 0.74 μg/dL), compared with that associated with placebo (2.82 ± 1.94 μg/dL; P = .033). The ACTH-stimulated peak cortisol concentrations were lower after treatment in cats receiving IGC (before, 8.5 ± 50.2 μg/dL; after, 2.9 ± 3.3 μg/dL, P = .0004), but not OGC (before, 8.0 ± 6.1 μg/dL; after, 6.0 ± 4.5 μg/dL, P = .07). Similarly, UC:Cr (0.8 ± 0.8) before IGC was lower than the value (5.02 ± 3.62; P = .019) after IGC. Compared with placebo, cats given OGC, but not IGC, had significantly lower total percentages of T and B cells. Lymphocyte proliferation was decreased in cats receiving OGC, but not IGC, in comparison with placebo (6.9 ± 3.3; 24.0 ± 6.5; 18.8 ± 14.0, respectively). Significantly more IL-10 mRNA transcription was detected in cats administered OGC or IGC, compared with placebo. Although IGC suppress the hypothalamic-pituitary-adrenocortical axis, IGC had minimal effects on the systemic adaptive immune system.",
keywords = "Adaptive immunity, Flunisolide, Glucocorticoid, Hypothalamic-pituitary- adrenal-axis",
author = "Reinero, {Carol R.} and Lisa Brownlee and Decile, {Kendra C.} and Bernard Seguin and Berghaus, {Roy D.} and Nelson, {Richard W} and Gershwin, {Laurel J}",
year = "2006",
month = "1",
doi = "10.1892/0891-6640(2006)20[57:IFSTHA]2.0.CO;2",
language = "English (US)",
volume = "20",
pages = "57--64",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats

AU - Reinero, Carol R.

AU - Brownlee, Lisa

AU - Decile, Kendra C.

AU - Seguin, Bernard

AU - Berghaus, Roy D.

AU - Nelson, Richard W

AU - Gershwin, Laurel J

PY - 2006/1

Y1 - 2006/1

N2 - Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases. Inhalant GC (IGC) maximize local efficacy and minimize systemic bioavailability. We evaluated systemic endocrine and immune effects of IGC (flunisolide, 250 μg/puff q12h) versus OGC (prednisone, 10 mg/d PO) and placebo. Six healthy cats received each drug for 2 weeks followed by a 1-month washout. Testing included determination of single early morning cortisol concentration, results of ACTH stimulation, the urine cortisol-to-creatinine ratio (UC : Cr), lymphocyte phenotype, lymphocyte blastogenesis, serum total IgA and IgM concentrations, and cytokine profiles. Significant differences between treatments were not apparent for serum immunoglobulin concentrations, or expression (mRNA) for the cytokines, interleukin (IL-) 2, IL-4, and IL-10, or gamma interferon. Single early morning cortisol concentration was lower for IGC (0.68 ± 0.74 μg/dL), compared with that associated with placebo (2.82 ± 1.94 μg/dL; P = .033). The ACTH-stimulated peak cortisol concentrations were lower after treatment in cats receiving IGC (before, 8.5 ± 50.2 μg/dL; after, 2.9 ± 3.3 μg/dL, P = .0004), but not OGC (before, 8.0 ± 6.1 μg/dL; after, 6.0 ± 4.5 μg/dL, P = .07). Similarly, UC:Cr (0.8 ± 0.8) before IGC was lower than the value (5.02 ± 3.62; P = .019) after IGC. Compared with placebo, cats given OGC, but not IGC, had significantly lower total percentages of T and B cells. Lymphocyte proliferation was decreased in cats receiving OGC, but not IGC, in comparison with placebo (6.9 ± 3.3; 24.0 ± 6.5; 18.8 ± 14.0, respectively). Significantly more IL-10 mRNA transcription was detected in cats administered OGC or IGC, compared with placebo. Although IGC suppress the hypothalamic-pituitary-adrenocortical axis, IGC had minimal effects on the systemic adaptive immune system.

AB - Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases. Inhalant GC (IGC) maximize local efficacy and minimize systemic bioavailability. We evaluated systemic endocrine and immune effects of IGC (flunisolide, 250 μg/puff q12h) versus OGC (prednisone, 10 mg/d PO) and placebo. Six healthy cats received each drug for 2 weeks followed by a 1-month washout. Testing included determination of single early morning cortisol concentration, results of ACTH stimulation, the urine cortisol-to-creatinine ratio (UC : Cr), lymphocyte phenotype, lymphocyte blastogenesis, serum total IgA and IgM concentrations, and cytokine profiles. Significant differences between treatments were not apparent for serum immunoglobulin concentrations, or expression (mRNA) for the cytokines, interleukin (IL-) 2, IL-4, and IL-10, or gamma interferon. Single early morning cortisol concentration was lower for IGC (0.68 ± 0.74 μg/dL), compared with that associated with placebo (2.82 ± 1.94 μg/dL; P = .033). The ACTH-stimulated peak cortisol concentrations were lower after treatment in cats receiving IGC (before, 8.5 ± 50.2 μg/dL; after, 2.9 ± 3.3 μg/dL, P = .0004), but not OGC (before, 8.0 ± 6.1 μg/dL; after, 6.0 ± 4.5 μg/dL, P = .07). Similarly, UC:Cr (0.8 ± 0.8) before IGC was lower than the value (5.02 ± 3.62; P = .019) after IGC. Compared with placebo, cats given OGC, but not IGC, had significantly lower total percentages of T and B cells. Lymphocyte proliferation was decreased in cats receiving OGC, but not IGC, in comparison with placebo (6.9 ± 3.3; 24.0 ± 6.5; 18.8 ± 14.0, respectively). Significantly more IL-10 mRNA transcription was detected in cats administered OGC or IGC, compared with placebo. Although IGC suppress the hypothalamic-pituitary-adrenocortical axis, IGC had minimal effects on the systemic adaptive immune system.

KW - Adaptive immunity

KW - Flunisolide

KW - Glucocorticoid

KW - Hypothalamic-pituitary- adrenal-axis

UR - http://www.scopus.com/inward/record.url?scp=32344433584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32344433584&partnerID=8YFLogxK

U2 - 10.1892/0891-6640(2006)20[57:IFSTHA]2.0.CO;2

DO - 10.1892/0891-6640(2006)20[57:IFSTHA]2.0.CO;2

M3 - Article

C2 - 16496924

AN - SCOPUS:32344433584

VL - 20

SP - 57

EP - 64

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 1

ER -